Mylan Tries To Escape Pharmacy's EpiPen Antitrust Suit

By Meghan Kelly · December 15, 2020, 5:46 PM EST

Mylan Pharmaceuticals has urged a Kansas federal judge to drop it from a suit alleging it inflated the price for the emergency allergy medication EpiPen, arguing the retail and online pharmacy...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Related Sections

Case Information

Case Title

In Re: Epipen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation

Case Number

2:17-md-02785

Court

Kansas

Nature of Suit

Personal Inj. Prod. Liability

Date Filed

August 04, 2017

Case Title

KPH Healthcare Services, Inc. v. Mylan N.V. et al

Case Number

2:20-cv-02065

Court

Kansas

Nature of Suit

Anti-Trust

Date Filed

February 14, 2020

Featured Stories

$95M Kaiser Row Tees Up Challenge For Fund Returns No Photo Available

Jennifer Mandato

Kaiser Foundation Health Plan’s lawsuit seeking $95 million in coverage for a recently settled whistleblower action raises an importan... (more story)

Abortion Pill Access, Tariff Questions And More In Court No Photo Available

Gianna Ferrarin

Law360 Healthcare Authority looks at drugmakers' intervention in federal litigation concerning mail-order abortion medication, questio... (more story)

How To Read FDA's Flip-Flop On Moderna Flu Vaccine No Photo Available

Yeji Jesse Lee

An unusual FDA reversal on a new flu vaccine is raising alarm bells for health experts and attorneys.